Zevra Therapeutics, Inc.ZVRANASDAQ
LOADING
|||
Switch Symbol:
Operating Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
105.83%
↑ 266% above average
Average (39q)
-63.72%
Historical baseline
Range
High:316.55%
Low:-1232.28%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 105.83% |
| Q2 2025 | -1224.86% |
| Q1 2025 | 65.22% |
| Q4 2024 | 43.54% |
| Q3 2024 | -14.76% |
| Q2 2024 | -16.15% |
| Q1 2024 | -39.64% |
| Q4 2023 | 4.51% |
| Q3 2023 | -145.75% |
| Q2 2023 | 51.27% |
| Q1 2023 | -38.67% |
| Q4 2022 | -39.65% |
| Q3 2022 | 73.25% |
| Q2 2022 | -1232.28% |
| Q1 2022 | 34.59% |
| Q4 2021 | -27.90% |
| Q3 2021 | -138.09% |
| Q2 2021 | -16.19% |
| Q1 2021 | 316.55% |
| Q4 2020 | -164.96% |
| Q3 2020 | -146.78% |
| Q2 2020 | 168.69% |
| Q1 2020 | 14.40% |
| Q4 2019 | -236.36% |
| Q3 2019 | 141.50% |
| Q2 2019 | 31.46% |
| Q1 2019 | -22.67% |
| Q4 2018 | 48.39% |
| Q3 2018 | -29.12% |
| Q2 2018 | 5.83% |
| Q1 2018 | -81.21% |
| Q4 2017 | 15.21% |
| Q3 2017 | -16.88% |
| Q2 2017 | -11.44% |
| Q1 2017 | 31.99% |
| Q4 2016 | -4.33% |
| Q3 2016 | -12.14% |
| Q2 2016 | -33.07% |
| Q1 2016 | 4.28% |
| Q4 2015 | -12.38% |